Geddes A M, Schnurr L P, Ball A P, McGhie D, Brookes G R, Wise R, Andrews J
Br Med J. 1977 Apr 30;1(6069):1126-8. doi: 10.1136/bmj.1.6069.1126.
Cefoxitin is a new cephamycin antibiotic that has recently become available for clinical trial. We report here the results of an uncontrolled trial of cefoxitin treatment in 31 hospital patients with various acute infections, 20 of whom were cured. Serum, urine, and bile concentrations of cefoxitin greatly exceeded the minimum inhibitory concentration (MIC) required for clinically important Gram-negative organisms. We conclude that cefoxitin will have a place in the management of serious infections, particularly in the abdominal cavity and renal tracts.
头孢西丁是一种新型头孢霉素抗生素，最近已可用于临床试验。我们在此报告对31例患有各种急性感染的住院患者进行头孢西丁治疗的非对照试验结果，其中20例治愈。头孢西丁的血清、尿液和胆汁浓度大大超过了临床上重要的革兰氏阴性菌所需的最低抑菌浓度（MIC）。我们得出结论，头孢西丁在严重感染的治疗中，特别是在腹腔和泌尿道感染的治疗中将会占有一席之地。
